RxDoctor Payments Data

Lauren Jones, APRN

Nurse Practitioner · Edgewood, KYNPI 1174772628

Payments from drug & device makers

$4,182in general payments, 2019–2025

Across 219 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$724
  • AbbVie$584
  • Astellas Pharma US Inc$428
  • Lilly USA, LLC$293
  • Pfizer$290
  • Amgen$219
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,99796%
  • Education$1854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,182 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$22,087
Medicare patients
99
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$64,397
MounjaroTirzepatide11$28,645
FarxigaDapagliflozin Propanediol22$22,588
JardianceEmpagliflozin12$17,083
EliquisApixaban17$12,428
Esomeprazole Magnesium17$3,550
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,509
Varenicline Tartrate17$1,829
Albuterol Sulfate HfaAlbuterol Sulfate72$1,708
Ventolin HfaAlbuterol Sulfate20$1,114
Potassium Chloride20$1,077
Rosuvastatin Calcium62$778
Fluticasone Propionate50$699
Levothyroxine Sodium87$692
Atorvastatin Calcium75$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$724$64,39738 claims
Lilly USA, LLCMounjaro$293$28,64511 claims
AstraZenecaFarxiga$204$22,58822 claims
Boehringer IngelheimJardiance$136$17,08312 claims
PfizerEliquis$290$12,42817 claims
AbbVieSynthroid$584$15115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Edgewood

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →